# Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer

> **NCT03246074** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 35 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Fostamatinib 100 mg bid and Paclitaxel
- **DRUG:** Fostamatinib 150 mg bid and Paclitaxel
- **DRUG:** Fostamatinib 200 mg bid and Paclitaxel

## Key facts

- **NCT ID:** NCT03246074
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-03
- **Primary completion:** 2022-08-09
- **Final completion:** 2023-04-03
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-10-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03246074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03246074, "Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03246074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*